Daniel Speiser

Publications | Mémoires et thèses

La recherche avancée est accessible via Serval

Les publications peuvent être gérées en accédant à Serval via MyUnil


359 publications

... | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 |
2008
 
Ex-vivo cytotoxic function by influenza specific CD8 effector T-cells from healthy humans in memory phase : P219
Touvrey C., Derre L., Rufer N., Romero P., Speiser D., 2008. pp. 50S-51S dans Annual Joint Meeting of the Swiss Societies for Pneumology, Paediatric Pneumology, Allergology and Immunology, Thoracic Surgery, Swiss Medical Weekly. Peer-reviewed.
[WoS][serval:BIB_8A289DB6CC44]
 
Identification of tumor-associated antigens by large-scale analysis of genes expressed in human colorectal cancer.
Alves P.M., Lévy N., Stevenson B.J., Bouzourene H., Theiler G., Bricard G., Viatte S., Ayyoub M., Vuilleumier H., Givel J.C. et al., 2008. Cancer Immunity, 8 p. 11.
[Pmid][serval:BIB_3C0CEE85B4C0]
 
Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides
Jandus C., Bioley G., Rivals J.P., Dudler J., Speiser D., Romero P., 2008. Arthritis and Rheumatism, 58 (8) pp. 2307-2317. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_620816C7D716]
 
Nouveautés dans l'immunothérapie du cancer [New developments in cancer immunotherapy]
Michielin O., Rufer N., Romero P., Laurent J., Cerottini J.P., Gugisberg D., Leyvraz S., Speiser D., 2008. Revue Médicale Suisse, 4 (158) pp. 1248-1251.
[Pmid][serval:BIB_C00741FF898D]
 
RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses.
Schmitt M., Schmitt A., Rojewski M.T., Chen J., Giannopoulos K., Fei F., Yu Y., Götz M., Heyduk M., Ritter G. et al., 2008. Blood, 111 (3) pp. 1357-1365.
[DOI][WoS][Pmid][serval:BIB_7F167123FF4C]
Selective accumulation of differentiated FOXP3(+) CD4 (+) T cells in metastatic tumor lesions from melanoma patients compared to peripheral blood
Jandus C., Bioley G., Speiser D.E., Romero P., 2008. Cancer Immunology, Immunotherapy, 57 (12) pp. 1795-1805. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_5C81771B51CC]
 
Tumour antigen specific CD8+T-cells from melanoma patients exert strong ex-vivo cytolytic activity
Mahnke Y., Devevre E., Baurngaertner P., Matter M., Rufer N., Rorner P., Speiser D., 2008. pp. 17S dans Annual Joint Meeting of the Swiss Societies for Pneumology, Paediatric Pneumology, Allergology and Immunology, Thoracic Surgery, Swiss Medical Weekly. Peer-reviewed.
[WoS][serval:BIB_045B613FBA08]
 
Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen
Speiser D. E., Baumgaertner P., Voelter V., Devevre E., Barbey C., Rufer N., Romero P., 2008. Proceedings of the National Academy of Sciences of the United States of America, 105 (10) pp. 3849-3854. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_2A13E6EEE57E]
2007
 
New approaches in metastatic melanoma: biological and molecular targeted therapies
Lejeune F. J., Rimoldi D., Speiser D., 2007/05. Expert Review of Anticancer Therapy, 7 (5) pp. 701-13.
[DOI][WoS][Pmid][serval:BIB_863EEE4CB3D9]
A novel population of human melanoma-specific CD8 T cells recognizes Melan-AMART-1 immunodominant nonapeptide but not the corresponding decapeptide.
Derré L., Ferber M., Touvrey C., Devevre E., Zoete V., Leimgruber A., Romero P., Michielin O., Lévy F., Speiser D.E., 2007. Journal of Immunology, 179 (11) pp. 7635-7645.
[URN][DOI][WoS][Pmid][serval:BIB_C81EFE777B85]
 
Combination of transient lymphodepletion with busulfan and fludarabine and peptide vaccination in a phase I clinical trial for patients with advanced melanoma.
Appay V., Voelter V., Rufer N., Reynard S., Jandus C., Gasparini D., Lienard D., Speiser D.E., Schneider P., Cerottini J.C. et al., 2007. Journal of Immunotherapy, 30 (2) pp. 240-250. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_1DFBEE45E211]
 
Four functionally distinct populations of human effector-memory CD8+ T lymphocytes.
Romero P., Zippelius A., Kurth I., Pittet M.J., Touvrey C., Iancu E.M., Corthesy P., Devevre E., Speiser D.E., Rufer N., 2007. Journal of Immunology, 178 (7) pp. 4112-4119. Peer-reviewed.
[WoS][Pmid][serval:BIB_82604B73B7F2]
IL-12 controls cytotoxicity of a novel subset of self-antigen-specific human CD28+ cytolytic T cells.
Barbey C., Baumgaertner P., Devevre E., Rubio-Godoy V., Derre L., Bricard G., Guillaume P., Luescher I.F., Liénard D., Cerottini J.C. et al., 2007. Journal of Immunology, 178 (6) pp. 3566-3574. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_34A31269CA86]
Immunogenicity of the carcinoembryonic antigen derived peptide 694 in HLA-A2 healthy donors and colorectal carcinoma patients.
Alves P.M., Viatte S., Fagerberg T., Michielin O., Bricard G., Bouzourene H., Vuilleumier H., Kruger T., Givel J.C., Lévy F. et al., 2007. Cancer immunology, immunotherapy, 56 (11) pp. 1795-1805. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_9EF18CF1C772]
In Vivo Persistence of Codominant Human CD8+ T Cell Clonotypes Is Not Limited by Replicative Senescence or Functional Alteration.
Derré L., Bruyninx M., Baumgaertner P., Devevre E., Corthesy P., Touvrey C., Mahnke Y.D., Pircher H., Voelter V., Romero P. et al., 2007. Journal of Immunology, 179 (4) pp. 2368-2379. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_96E2EC572F21]
Molecular and immunological evaluation of the expression of cancer/testis gene products in human colorectal cancer.
Alves P.M., Lévy N., Bouzourene H., Viatte S., Bricard G., Ayyoub M., Vuilleumier H., Givel J.C., Halkic N., Speiser D.E. et al., 2007. Cancer immunology, immunotherapy, 56 (6) pp. 839-847. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_483359E44050]
 
Sensitive gene expression profiling of human T cell subsets reveals parallel post-thymic differentiation for CD4+ and CD8+ lineages.
Appay V., Bosio A., Lokan S., Wiencek Y., Biervert C., Küsters D., Devevre E., Speiser D., Romero P., Rufer N. et al., 2007. Journal of Immunology, 179 (11) pp. 7406-7414. Peer-reviewed.
[WoS][Pmid][serval:BIB_D1BEBB48617A]
 
Tissue homing and persistence of defined antigen-specific CD8+ tumor-reactive T-cell clones in long-term melanoma survivors.
Le Gal F.A., Widmer V.M., Dutoit V., Rubio-Godoy V., Schrenzel J., Walker P.R., Romero P.J., Valmori D., Speiser D.E., Dietrich P.Y., 2007. Journal of Investigative Dermatology, 127 (3) pp. 622-629.
[DOI][WoS][Pmid][serval:BIB_E2A0EDDC35A5]
2006
 
A novel approach to characterize clonality and differentiation of human melanoma-specific T cell responses: spontaneous priming and efficient boosting by vaccination.
Speiser D.E., Baumgaertner P., Barbey C., Rubio-Godoy V., Moulin A., Corthesy P., Devevre E., Dietrich P.Y., Rimoldi D., Liénard D. et al., 2006. Journal of Immunology, 177 (2) pp. 1338-1348. Peer-reviewed.
[WoS][Pmid][serval:BIB_DAB362027941]
 
Decreased specific CD8+ T cell cross-reactivity of antigen recognition following vaccination with Melan-A peptide.
Appay V., Speiser D.E., Rufer N., Reynard S., Barbey C., Cerottini J.C., Leyvraz S., Pinilla C., Romero P., 2006. European journal of immunology, 36 (7) pp. 1805-14. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_48BEA2BF1B81]
 
Dextramers: new generation of fluorescent MHC class I/peptide multimers for visualization of antigen-specific CD8+ T cells.
Batard P., Peterson D.A., Devêvre E., Guillaume P., Cerottini J.C., Rimoldi D., Speiser D.E., Winther L., Romero P., 2006. Journal of immunological methods, 310 (1-2) pp. 136-148. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D79B52C290F3]
 
Ex vivo characterization of allo-MHC-restricted T cells specific for a single MHC-peptide complex.
Pittet M.J., Gati A., Le Gal F.A., Bioley G., Guillaume P., de Smedt M., Plum J., Speiser D.E., Cerottini J.C., Dietrich P.Y. et al., 2006. Journal of immunology, 176 (4) pp. 2330-2336. Peer-reviewed.
[WoS][Pmid][serval:BIB_9BC901FAC322]
Ex vivo detectable human CD8 T-cell responses to cancer-testis antigens.
Baumgaertner P., Rufer N., Devevre E., Derre L., Rimoldi D., Geldhof C., Voelter V., Liénard D., Romero P., Speiser D.E., 2006. Cancer Research, 66 (4) pp. 1912-1916. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D9CFEA5BF1AA]
 
Fluorescence-activated cell sorting and cloning of bona fide CD8+ CTL with reversible MHC-peptide and antibody Fab' conjugates.
Guillaume P., Baumgaertner P., Angelov G.S., Speiser D., Luescher I.F., 2006. Journal of immunology, 177 (6) pp. 3903-3912. Peer-reviewed.
[WoS][Pmid][serval:BIB_D2C4FBD22187]
 
Human effector CD8+ T lymphocytes express TLR3 as a functional coreceptor.
Tabiasco J., Devêvre E., Rufer N., Salaun B., Cerottini J.C., Speiser D., Romero P., 2006. Journal of immunology, 177 (12) pp. 8708-8713. Peer-reviewed.
[WoS][Pmid][serval:BIB_083AACA66516]
 
Immuno-monitoring of CD8+ T cells in whole blood versus PBMC samples.
Appay V., Reynard S., Voelter V., Romero P., Speiser D.E., Leyvraz S., 2006. Journal of immunological methods, 309 (1-2) pp. 192-9. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_23FAB61E7012]
 
Impact of orthologous melan-A peptide immunizations on the anti-self melan-A/HLA-A2 T cell cross-reactivity.
Colombetti S., Fagerberg T., Baumgärtner P., Chapatte L., Speiser D.E., Rufer N., Michielin O., Lévy F., 2006. Journal of Immunology, 176 (11) pp. 6560-6567. Peer-reviewed.
[WoS][Pmid][serval:BIB_FF36BB0A3BB5]
 
Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers.
Bioley G., Jandus C., Tuyaerts S., Rimoldi D., Kwok W.W., Speiser D.E., Tiercy J.M., Thielemans K., Cerottini J.C., Romero P., 2006. Journal of immunology, 177 (10) pp. 6769-6779. Peer-reviewed.
[WoS][Pmid][serval:BIB_DE716DD57709]
 
New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site.
Appay V., Jandus C., Voelter V., Reynard S., Coupland S.E., Rimoldi D., Lienard D., Guillaume P., Krieg A.M., Cerottini J.C. et al., 2006. Journal of Immunology, 177 (3) pp. 1670-1678. Peer-reviewed.
[WoS][Pmid][serval:BIB_8EEEF1A119B7]
 
The human T cell response to melanoma antigens.
Romero P., Cerottini J.C., Speiser D.E., 2006. Advances in immunology, 92 pp. 187-224. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D0C3989F2AD9]
2005
 
Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells.
van Baren N., Bonnet M.C., Dréno B., Khammari A., Dorval T., Piperno-Neumann S., Liénard D., Speiser D., Marchand M., Brichard V.G. et al., 2005/12. Journal of Clinical Oncology, 23 (35) pp. 9008-9021. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_3B9C918EC585]
 
Immunological techniques: ex vivo characterization of T cell-mediated immune responses in cancer
Speiser D. E., 2005/08. Current Opinion in Immunology, 17 (4) pp. 419-22.
[DOI][WoS][Pmid][serval:BIB_2374750F60D9]
 
CD4+ T cell responses to SSX-4 in melanoma patients
Ayyoub M., Merlo A., Hesdorffer C. S., Rimoldi D., Speiser D., Cerottini J. C., Chen Y. T., Old L. J., Stevanovic S., Valmori D., 2005/04. Journal of Immunology, 174 (8) pp. 5092-9.
[WoS][Pmid][serval:BIB_62F457F17305]
Progress and controversies in developing cancer vaccines.
Slingluff C.L., Speiser D.E., 2005/04. Journal of Translational Medicine, 3 (1) p. 18.
[URN][DOI][Pmid][serval:BIB_DB417DAE2FD5]
 
Efficient homologous prime-boost strategies for T cell vaccination based on virus-like particles
Schwarz K., Meijerink E., Speiser D. E., Tissot A. C., Cielens I., Renhof R., Dishlers A., Pumpens P., Bachmann M. F., 2005/03. European Journal of Immunology, 35 (3) pp. 816-21.
[DOI][WoS][Pmid][serval:BIB_53B11B2BEFAF]
 
Distinct but overlapping T helper epitopes in the 37-58 region of SSX-2
Ayyoub M., Merlo A., Hesdorffer C. S., Speiser D., Rimoldi D., Cerottini J. C., Ritter G., Chen Y. T., Old L. J., Stevanovic S. et al., 2005/01. Clinical Immunology, 114 (1) pp. 70-8.
[DOI][WoS][Pmid][serval:BIB_4FDC597DC998]
Naturally acquired MAGE-A10- and SSX-2-specific CD8+ T cell responses in patients with hepatocellular carcinoma.
Bricard G., Bouzourene H., Martinet O., Rimoldi D., Halkic N., Gillet M., Chaubert P., Macdonald H.R., Romero P., Cerottini J.C. et al., 2005. Journal of immunology, 174 (3) pp. 1709-1716. Peer-reviewed.
[URN][WoS][Pmid][serval:BIB_1874344F750A]
 
Optimum in vitro expansion of human antigen-specific CD8 T cells for adoptive transfer therapy.
Montes M., Rufer N., Appay V., Reynard S., Pittet M.J., Speiser D.E., Guillaume P., Cerottini J.C., Romero P., Leyvraz S., 2005. Clinical and experimental immunology, 142 (2) pp. 292-302. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_1AC9A366B9C2]
 
Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909.
Speiser D.E., Liénard D., Rufer N., Rubio-Godoy V., Rimoldi D., Lejeune F., Krieg A.M., Cerottini J.C., Romero P., 2005. Journal of Clinical Investigation, 115 (3) pp. 739-746. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_1F6FBB6665E9]
 
Recent advances in tumour antigen-specific therapy: in vivo veritas.
Mahnke Y.D., Speiser D., Luescher I.F., Cerottini J.C., Romero P., 2005. International journal of cancer, 113 (2) pp. 173-178. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_EAC0A57F4F75]
 
Tinkering with nature: the tale of optimizing peptide based cancer vaccines.
Michielin O., Blanchet J.S., Fagerberg T., Valmori D., Rubio-Godoy V., Speiser D., Ayyoub M., Alves P., Luescher I., Gairin J.E. et al., 2005. Cancer treatment and research, 123 pp. 267-291.
[Pmid][serval:BIB_D7E587D63564]
 
Toward improved immunocompetence of adoptively transferred CD8+ T cells.
Speiser D.E., Romero P., 2005. Journal of Clinical Investigation, 115 (6) pp. 1467-1469.
[DOI][WoS][Pmid][serval:BIB_66C9C19BF9A2]
Tumor cell recognition efficiency by T cells.
Speiser D.E., Cerottini J.C., Romero P., 2005. PLoS medicine, 2 (3) pp. e77; author reply e95.
[URN][DOI][WoS][Pmid][serval:BIB_ABEECE931FD5]
2004
 
Identification of an SSX-2 epitope presented by dendritic cells to circulating autologous CD4+ T cells
Ayyoub M., Hesdorffer C. S., Metthez G., Stevanovic S., Ritter G., Chen Y. T., Old L. J., Speiser D., Cerottini J. C., Valmori D., 2004/06. Journal of Immunology, 172 (11) pp. 7206-11.
[WoS][Pmid][serval:BIB_C4A2AB3F745F]
 
An immunodominant SSX-2-derived epitope recognized by CD4+ T cells in association with HLA-DR
Ayyoub M., Hesdorffer C. S., Montes M., Merlo A., Speiser D., Rimoldi D., Cerottini J. C., Ritter G., Scanlan M., Old L. J. et al., 2004/04. Journal of Clinical Investigation, 113 (8) pp. 1225-33.
[DOI][WoS][Pmid][serval:BIB_E82E81398C61]
 
CpG-A and CpG-B oligonucleotides differentially enhance human peptide-specific primary and memory CD8+ T-cell responses in vitro
Rothenfusser S., Hornung V., Ayyoub M., Britsch S., Towarowski A., Krug A., Sarris A., Lubenow N., Speiser D., Endres S. et al., 2004/03. Blood, 103 (6) pp. 2162-9.
[DOI][WoS][Pmid][serval:BIB_814DD173802B]
 
Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance.
Zippelius A., Batard P., Rubio-Godoy V., Bioley G., Liénard D., Lejeune F., Rimoldi D., Guillaume P., Meidenbauer N., Mackensen A. et al., 2004. Cancer research, 64 (8) pp. 2865-73. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_31698]
 
Ex vivo analysis of human antigen-specific CD8+ T-cell responses: quality assessment of fluorescent HLA-A2 multimer and interferon-gamma ELISPOT assays for patient immune monitoring.
Speiser D.E., Pittet M.J., Guillaume P., Lubenow N., Hoffman E., Cerottini J.C., Romero P., 2004. Journal of Immunotherapy, 27 (4) pp. 298-308.
[DOI][WoS][Pmid][serval:BIB_8BF0E4D9B030]
 
Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA.
Liénard D., Rimoldi D., Marchand M., Dietrich P.Y., van Baren N., Geldhof C., Batard P., Guillaume P., Ayyoub M., Pittet M.J. et al., 2004. Cancer Immunity, 4 p. 4.
[Pmid][serval:BIB_247C151A7AD3]
 
Human thymus exports naive CD8 T cells that can home to nonlymphoid tissues.
Zippelius A., Bioley G., Le Gal F.A., Rufer N., Brandes M., Batard P., De Smedt M., Plum J., Speiser D.E., Cerottini J.C. et al., 2004. Journal of Immunology, 172 (5) pp. 2773-2777.
[WoS][Pmid][serval:BIB_31699]
Monitoring tumor antigen specific T-cell responses in cancer patients and phase I clinical trials of peptide-based vaccination.
Romero P., Cerottini J.C., Speiser D.E., 2004. Cancer Immunology, Immunotherapy, 53 (3) pp. 249-255.
[URN][DOI][WoS][Pmid][serval:BIB_9D31B462B0D5]
2003
 
Lack of BRAF mutations in uveal melanoma
Rimoldi D., Salvi S., Lienard D., Lejeune F. J., Speiser D., Zografos L., Cerottini J. C., 2003/09. Cancer Research, 63 (18) pp. 5712-5.
[WoS][Pmid][serval:BIB_5005AEA40B02]
 
CpG-A oligonucleotides induce a monocyte-derived dendritic cell-like phenotype that preferentially activates CD8 T cells
Krug A., Rothenfusser S., Selinger S., Bock C., Kerkmann M., Battiany J., Sarris A., Giese T., Speiser D., Endres S. et al., 2003/04. Journal of Immunology, 170 (7) pp. 3468-77.
[WoS][Pmid][serval:BIB_FC3321B173EF]
 
Efficient T cell repertoire selection in tetraparental chimeric mice independent of thymic epithelial MHC
Martinic M. M., Rulicke T., Althage A., Odermatt B., Hochli M., Lamarre A., Dumrese T., Speiser D. E., Kyburz D., Hengartner H. et al., 2003/02. Proceedings of the National Academy of Sciences of the United States of America, 100 (4) pp. 1861-6.
[DOI][WoS][Pmid][serval:BIB_0C0DA4D9366A]
 
Activation of human melanoma reactive CD8+ T cells by vaccination with an immunogenic peptide analog derived from Melan-A/melanoma antigen recognized by T cells-1.
Ayyoub M., Zippelius A., Pittet M.J., Rimoldi D., Valmori D., Cerottini J.C., Romero P., Lejeune F., Liénard D., Speiser D.E., 2003. Clinical Cancer Research, 9 (2) pp. 669-677. Peer-reviewed.
[WoS][Pmid][serval:BIB_76A8B8796443]
 
Alpha 3 domain mutants of peptide/MHC class I multimers allow the selective isolation of high avidity tumor-reactive CD8 T cells.
Pittet M.J., Rubio-Godoy V., Bioley G., Guillaume P., Batard P., Speiser D., Luescher I., Cerottini J.C., Romero P., Zippelius A., 2003. Journal of immunology, 171 (4) pp. 1844-1849. Peer-reviewed.
[WoS][Pmid][serval:BIB_57B6C853FE89]
 
Disease-driven T cell activation predicts immune responses to vaccination against melanoma.
Speiser D.E., Rimoldi D., Batard P., Liénard D., Lejeune F., Cerottini J.C., Romero P., 2003. Cancer Immunity, 3 p. 12.
[Pmid][serval:BIB_299BAF0B8146]
 
Endotoxin and asthma
Speiser D. E., Zippelius A., 2003/01. New England Journal of Medicine, 348 (2) pp. 171-4; author reply 171-4.
[Pmid][serval:BIB_644B5751F521]
 
Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells.
Speiser D.E., Pittet M.J., Rimoldi D., Guillaume P., Luescher I.F., Liénard D., Lejeune F., Cerottini J.C., Romero P., 2003. Seminars in cancer biology, 13 (6) pp. 461-72. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_5A549B6675C0]
 
Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine.
Valmori D., Dutoit V., Ayyoub M., Rimoldi D., Guillaume P., Liénard D., Lejeune F., Cerottini J.C., Romero P., Speiser D.E., 2003. Cancer immunity : a journal of the Academy of Cancer Immunology, 3 p. 15.
[Pmid][serval:BIB_09BC85EA8C44]
 
Tumor-reactive, SSX-2-specific CD8+ T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients.
Ayyoub M., Rimoldi D., Guillaume P., Romero P., Cerottini J.C., Valmori D., Speiser D., 2003. Cancer Research, 63 (17) pp. 5601-5606.
[WoS][Pmid][serval:BIB_6F341245D7B1]
2002
 
Sister cytotoxic CD8+ T cell clones differing in natural killer inhibitory receptor expression in human astrocytoma
Perrin G., Speiser D., Porret A., Quiquerez A. L., Walker P. R., Dietrich P. Y., 2002/04. Immunology Letters, 81 (2) pp. 125-32.
[DOI][WoS][Pmid][serval:BIB_AC243B538799]
Tumor growth enhances cross-presentation leading to limited T cell activation without tolerance
Nguyen L. T., Elford A. R., Murakami K., Garza K. M., Schoenberger S. P., Odermatt B., Speiser D. E., Ohashi P. S., 2002/02. Journal of Experimental Medicine, 195 (4) pp. 423-35.
[URN][DOI][WoS][Pmid][serval:BIB_061A829BB9D3]
 
Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma.
Romero P., Valmori D., Pittet M.J., Zippelius A., Rimoldi D., Lévy F., Dutoit V., Ayyoub M., Rubio-Godoy V., Michielin O. et al., 2002. Immunological reviews, 188 pp. 81-96. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_F417556ABB91]
 
Can hTERT peptide (540-548) -specific CD8 T cells recognize and kill tumor cells?
Speiser D.E., Cerottini J.C., Romero P., 2002. Cancer Immunity, 2 p. 14.
[Pmid][serval:BIB_D859CE8A54F9]
 
CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide.
Miconnet I., Koenig S., Speiser D., Krieg A., Guillaume P., Cerottini J.C., Romero P., 2002. Journal of Immunology, 168 (3) pp. 1212-1218. Peer-reviewed.
[WoS][Pmid][serval:BIB_B25DC479FAB9]
 
Functional avidity of tumor antigen-specific CTL recognition directly correlates with the stability of MHC/peptide multimer binding to TCR.
Dutoit V., Rubio-Godoy V., Doucey M.A., Batard P., Liénard D., Rimoldi D., Speiser D., Guillaume P., Cerottini J.C., Romero P. et al., 2002. Journal of Immunology, 168 (3) pp. 1167-1171. Peer-reviewed.
[WoS][Pmid][serval:BIB_75BF5C509C22]
 
In vivo activation of melanoma-specific CD8(+) T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells.
Speiser D.E., Liénard D., Pittet M.J., Batard P., Rimoldi D., Guillaume P., Cerottini J.C., Romero P., 2002. European journal of immunology, 32 (3) pp. 731-41. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_AEF4D5271253]
 
Melan-A/MART-1-specific CD8 T cells: from thymus to tumor.
Pittet M.J., Zippelius A., Valmori D., Speiser D.E., Cerottini J.C., Romero P., 2002. Trends in Immunology, 23 (7) pp. 325-328. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_5CA35E84A64C]
 
Proteasome-assisted identification of a SSX-2-derived epitope recognized by tumor-reactive CTL infiltrating metastatic melanoma.
Ayyoub M., Stevanovic S., Sahin U., Guillaume P., Servis C., Rimoldi D., Valmori D., Romero P., Cerottini J.C., Rammensee H.G. et al., 2002. Journal of Immunology, 168 (4) pp. 1717-1722.
[WoS][Pmid][serval:BIB_EDDA88773A60]
 
Therapeutic cancer vaccines based on molecularly defined human tumor antigens.
Romero P., Pittet M., Dutoit V., Zippelius A., Liénard D., Lejeune F., Guillaume P., Rimoldi D., Valmori D., Speiser D.E. et al., 2002. Vaccine, 20 Suppl 4 pp. A2-7. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A1891852C369]
Thymic selection generates a large T cell pool recognizing a self-peptide in humans.
Zippelius A., Pittet M.J., Batard P., Rufer N., de Smedt M., Guillaume P., Ellefsen K., Valmori D., Liénard D., Plum J. et al., 2002. The Journal of experimental medicine, 195 (4) pp. 485-494. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_23787]
2001
 
The activatory receptor 2B4 is expressed in vivo by human CD8+ effector alpha beta T cells
Speiser D. E., Colonna M., Ayyoub M., Cella M., Pittet M. J., Batard P., Valmori D., Guillaume P., Lienard D., Cerottini J. C. et al., 2001/12. Journal of Immunology, 167 (11) pp. 6165-70.
[WoS][Pmid][serval:BIB_35F0AFCBA261]
 
Discrepancy between ELISPOT IFN-gamma secretion and binding of A2/peptide multimers to TCR reveals interclonal dissociation of CTL effector function from TCR-peptide/MHC complexes half-life.
Rubio-Godoy V., Dutoit V., Rimoldi D., Lienard D., Lejeune F., Speiser D., Guillaume P., Cerottini J.C., Romero P., Valmori D., 2001/08. Proceedings of the National Academy of Sciences of the United States of America, 98 (18) pp. 10302-10307. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_8C526C41A0DD]
 
Ex vivo analysis of tumor antigen specific CD8+ T cell responses using MHC/peptide tetramers in cancer patients.
Pittet M.J., Speiser D.E., Valmori D., Rimoldi D., Liénard D., Lejeune F., Cerottini J.C., Romero P., 2001/07. International immunopharmacology, 1 (7) pp. 1235-1247. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_1563F678BF1F]
 
Ex vivo IFN-gamma secretion by circulating CD8 T lymphocytes: implications of a novel approach for T cell monitoring in infectious and malignant diseases.
Pittet M.J., Zippelius A., Speiser D.E., Assenmacher M., Guillaume P., Valmori D., Liénard D., Lejeune F., Cerottini J.C., Romero P., 2001/06. Journal of Immunology, 166 (12) pp. 7634-7640. Peer-reviewed.
[WoS][Pmid][serval:BIB_9A06E84F1CD5]
 
Expansion and functional maturation of human tumor antigen-specific CD8+ T cells after vaccination with antigenic peptide.
Pittet M.J., Speiser D.E., Liénard D., Valmori D., Guillaume P., Dutoit V., Rimoldi D., Lejeune F., Cerottini J.C., Romero P., 2001/03. Clinical Cancer Research, 7 (3 Suppl.) pp. 796s-803s. Peer-reviewed.
[WoS][Pmid][serval:BIB_09C135FF1AE1]
 
CD8+ T-cell response to NY-ESO-1: relative antigenicity and in vitro immunogenicity of natural and analogue sequences.
Romero P., Dutoit V., Rubio-Godoy V., Liénard D., Speiser D., Guillaume P., Servis K., Rimoldi D., Cerottini J.C., Valmori D., 2001. Clinical Cancer Research, 7 (3 Suppl.) pp. 766-772. Peer-reviewed.
[WoS][Pmid][serval:BIB_15537C0B1F5C]
 
Heterogeneous T-cell response to MAGE-A10(254-262): high avidity-specific cytolytic T lymphocytes show superior antitumor activity.
Dutoit V., Rubio-Godoy V., Dietrich P.Y., Quiqueres A.L., Schnuriger V., Rimoldi D., Liénard D., Speiser D., Guillaume P., Batard P. et al., 2001. Cancer research, 61 (15) pp. 5850-6. Peer-reviewed.
[WoS][Pmid][serval:BIB_0A0D935E2D5A]
 
Human CD8(+) T cells expressing HLA-DR and CD28 show telomerase activity and are distinct from cytolytic effector T cells.
Speiser D.E., Migliaccio M., Pittet M.J., Valmori D., Liénard D., Lejeune F., Reichenbach P., Guillaume P., Lüscher I., Cerottini J.C. et al., 2001. European journal of immunology, 31 (2) pp. 459-66. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C73B97B91E0C]
 
Lack of tumor recognition by hTERT peptide 540-548-specific CD8(+) T cells from melanoma patients reveals inefficient antigen processing.
Ayyoub M., Migliaccio M., Guillaume P., Liénard D., Cerottini J.C., Romero P., Lévy F., Speiser D.E., Valmori D., 2001. European journal of immunology, 31 (9) pp. 2642-51. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_5B44AAEC8764]
2000
 
Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients.
Valmori D., Dutoit V., Liénard D., Rimoldi D., Pittet M.J., Champagne P., Ellefsen K., Sahin U., Speiser D., Lejeune F. et al., 2000/08. Cancer research, 60 (16) pp. 4499-4506. Peer-reviewed.
[WoS][Pmid][serval:BIB_99DF5B4C6096]
 
Tetramer-guided analysis of TCR beta-chain usage reveals a large repertoire of melan-A-specific CD8+ T cells in melanoma patients.
Valmori D., Dutoit V., Liénard D., Lejeune F., Speiser D., Rimoldi D., Cerundolo V., Dietrich P.Y., Cerottini J.C., Romero P., 2000/07. Journal of Immunology, 165 (1) pp. 533-538. Peer-reviewed.
[WoS][Pmid][serval:BIB_942EB73825A2]
 
Cutting edge: cytolytic effector function in human circulating CD8+ T cells closely correlates with CD56 surface expression
Pittet M. J., Speiser D. E., Valmori D., Cerottini J. C., Romero P., 2000/02. Journal of Immunology, 164 (3) pp. 1148-52.
[WoS][Pmid][serval:BIB_EBA789CA2CFC]
 
TNF receptor 1 (TNFR1) and CD95 are not required for T cell deletion after virus infection but contribute to peptide-induced deletion under limited conditions
Nguyen L. T., McKall-Faienza K., Zakarian A., Speiser D. E., Mak T. W., Ohashi P. S., 2000/02. European Journal of Immunology, 30 (2) pp. 683-8.
[DOI][WoS][Pmid][serval:BIB_BF2D7A2D09E9]
 
Efficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and nonprimary open reading frame-derived CTL epitopes in melanoma.
Rimoldi D., Rubio-Godoy V., Dutoit V., Lienard D., Salvi S., Guillaume P., Speiser D., Stockert E., Spagnoli G., Servis C. et al., 2000. Journal of Immunology, 165 (12) pp. 7253-7261.
[WoS][Pmid][serval:BIB_617E760EBF32]
 
Immune monitoring in cancer immunotherapy.
Romero P., Pittet M.J., Valmori D., Speiser D.E., Cerundolo V., Liénard D., Lejeune F., Cerottini J.C., 2000. Ernst Schering Research Foundation workshop 30 pp. 75-97.
[Pmid][serval:BIB_27E99580ED6E]
1999
High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals
Pittet M. J., Valmori D., Dunbar P. R., Speiser D. E., Lienard D., Lejeune F., Fleischhauer K., Cerundolo V., Cerottini J. C., Romero P., 1999/09. Journal of Experimental Medicine, 190 (5) pp. 705-15.
[URN][DOI][WoS][Pmid][serval:BIB_8543B820A159]
 
TRAF2 deficiency results in hyperactivity of certain TNFR1 signals and impairment of CD40-mediated responses
Nguyen L. T., Duncan G. S., Mirtsos C., Ng M., Speiser D. E., Shahinian A., Marino M. W., Mak T. W., Ohashi P. S., Yeh W. C., 1999/09. Immunity, 11 (3) pp. 379-89.
[DOI][WoS][Pmid][serval:BIB_E808895C55DE]
 
Absence of co-stimulation and not the intensity of TCR signaling is critical for the induction of T cell unresponsiveness in vivo
Bachmann M. F., Speiser D. E., Mak T. W., Ohashi P. S., 1999/07. European Journal of Immunology, 29 (7) pp. 2156-66.
[DOI][WoS][Pmid][serval:BIB_1537F350F8FC]
 
Analysis of the cytolytic T lymphocyte response of melanoma patients to the naturally HLA-A*0201-associated tyrosinase peptide 368-376.
Valmori D., Pittet M.J., Vonarbourg C., Rimoldi D., Liénard D., Speiser D., Dunbar R., Cerundolo V., Cerottini J.C., Romero P., 1999. Cancer research, 59 (16) pp. 4050-5. Peer-reviewed.
[WoS][Pmid][serval:BIB_3B803475E5BD]
 
CD28-negative cytolytic effector T cells frequently express NK receptors and are present at variable proportions in circulating lymphocytes from healthy donors and melanoma patients.
Speiser D.E., Valmori D., Rimoldi D., Pittet M.J., Liénard D., Cerundolo V., MacDonald H.R., Cerottini J.C., Romero P., 1999. European journal of immunology, 29 (6) pp. 1990-1999. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D53515764F1B]
In vivo expression of natural killer cell inhibitory receptors by human melanoma-specific cytolytic T lymphocytes.
Speiser D.E., Pittet M.J., Valmori D., Dunbar R., Rimoldi D., Liénard D., MacDonald H.R., Cerottini J.C., Cerundolo V., Romero P., 1999. The Journal of experimental medicine, 190 (6) pp. 775-782. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_CDA12DB53A1D]
Optimal activation of tumor-reactive T cells by selected antigenic peptide analogues.
Valmori D., Fonteneau J.F., Valitutti S., Gervois N., Dunbar R., Liénard D., Rimoldi D., Cerundolo V., Jotereau F., Cerottini J.C. et al., 1999. International immunology, 11 (12) pp. 1971-80. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_943F39FA15D7]
1998
 
Inhibition of TCR triggering by a spectrum of altered peptide ligands suggests the mechanism for TCR antagonism
Bachmann M. F., Speiser D. E., Zakarian A., Ohashi P. S., 1998/10. European Journal of Immunology, 28 (10) pp. 3110-9.
[WoS][Pmid][serval:BIB_3275DD7EE408]
 
Tumor defense by murine cytotoxic T cells specific for peptide bound to nonclassical MHC class I
Griffiths E., Ong H., Soloski M. J., Bachmann M. F., Ohashi P. S., Speiser D. E., 1998/10. Cancer Research, 58 (20) pp. 4682-7.
[WoS][Pmid][serval:BIB_3906FB0FB78D]
 
Alloreactive cytotoxic T cells recognize minor transplantation antigens presented by major histocompatibility complex class Ib molecules
Speiser D. E., Bachmann M. F., Soloski M. J., Forman J., Ohashi P. S., 1998/09. Transplantation, 66 (5) pp. 646-50.
[DOI][WoS][Pmid][serval:BIB_63AF0053C9C7]
 
Activation of cytotoxic T cells by solid tumours?
Speiser D. E., Ohashi P. S., 1998/03. Cellular and Molecular Life Sciences, 54 (3) pp. 263-71.
[DOI][WoS][Pmid][serval:BIB_B4490BF0F8AE]
 
Normal responsiveness of CTLA-4-deficient anti-viral cytotoxic T cells
Bachmann M. F., Waterhouse P., Speiser D. E., McKall-Faienza K., Mak T. W., Ohashi P. S., 1998/01. Journal of Immunology, 160 (1) pp. 95-100.
[WoS][Pmid][serval:BIB_BBFDC6D20CEB]
1997
 
Four types of Ca2+ signals in naive CD8+ cytotoxic T cells after stimulation with T cell agonists, partial agonists and antagonists
Bachmann M. F., Mariathasan S., Bouchard D., Speiser D. E., Ohashi P. S., 1997/12. European Journal of Immunology, 27 (12) pp. 3414-9.
[DOI][WoS][Pmid][serval:BIB_DDCB74AE20FD]
 
Altered peptide ligands trigger perforin- rather than Fas-dependent cell lysis
Bachmann M. F., Ohteki T., Faienza K. M., Zakarian A., Kagi D., Speiser D. E., Ohashi P. S., 1997/11. Journal of Immunology, 159 (9) pp. 4165-70.
[WoS][Pmid][serval:BIB_6E509B10BF97]
 
Early lethality, functional NF-kappaB activation, and increased sensitivity to TNF-induced cell death in TRAF2-deficient mice
Yeh W. C., Shahinian A., Speiser D., Kraunus J., Billia F., Wakeham A., de la Pompa J. L., Ferrick D., Hum B., Iscove N. et al., 1997/11. Immunity, 7 (5) pp. 715-25.
[DOI][WoS][Pmid][serval:BIB_1E0786F63F72]
 
Distinct roles for LFA-1 and CD28 during activation of naive T cells: adhesion versus costimulation
Bachmann M. F., McKall-Faienza K., Schmits R., Bouchard D., Beach J., Speiser D. E., Mak T. W., Ohashi P. S., 1997/10. Immunity, 7 (4) pp. 549-57.
[DOI][WoS][Pmid][serval:BIB_515AFB41850C]
 
Peptide-induced T cell receptor down-regulation on naive T cells predicts agonist/partial agonist properties and strictly correlates with T cell activation
Bachmann M. F., Oxenius A., Speiser D. E., Mariathasan S., Hengartner H., Zinkernagel R. M., Ohashi P. S., 1997/09. European Journal of Immunology, 27 (9) pp. 2195-203.
[DOI][WoS][Pmid][serval:BIB_4A256FBEA846]
 
Functional management of an antiviral cytotoxic T-cell response
Bachmann M. F., Speiser D. E., Ohashi P. S., 1997/08. Journal of Virology, 71 (8) pp. 5764-8.
[WoS][Pmid][serval:BIB_E269B4FE17F3]
 
Self antigens expressed by solid tumors Do not efficiently stimulate naive or activated T cells: implications for immunotherapy
Speiser D. E., Miranda R., Zakarian A., Bachmann M. F., McKall-Faienza K., Odermatt B., Hanahan D., Zinkernagel R. M., Ohashi P. S., 1997/08. Journal of Experimental Medicine, 186 (5) pp. 645-53.
[DOI][WoS][Pmid][serval:BIB_C5DCAE58B25B]
 
Haploidentical family member transplants for patients with chronic myeloid leukaemia: a report of the Chronic Leukaemia Working Party of off European Group for Blood and Marrow Transplantation (EBMT)
Speiser D. E., Hermans J., van Biezen A., Starobinski M., Jeannet M., Jacobsen N., Niederwieser D., Gratwohl A., Apperley J. F., 1997/06. Bone Marrow Transplantation, 19 (12) pp. 1197-203.
[DOI][WoS][Pmid][serval:BIB_DDC6803C30C7]
 
TNF receptor p55 controls early acute graft-versus-host disease
Speiser D. E., Bachmann M. F., Frick T. W., McKall-Faienza K., Griffiths E., Pfeffer K., Mak T. W., Ohashi P. S., 1997/06. Journal of Immunology, 158 (11) pp. 5185-90.
[WoS][Pmid][serval:BIB_6E975FC92264]
 
A regulatory role for TRAF1 in antigen-induced apoptosis of T cells
Speiser D. E., Lee S. Y., Wong B., Arron J., Santana A., Kong Y. Y., Ohashi P. S., Choi Y., 1997/05. Journal of Experimental Medicine, 185 (10) pp. 1777-83.
[DOI][WoS][Pmid][serval:BIB_56AA7436F9BC]
 
Acute graft-versus-host disease without costimulation via CD28
Speiser D. E., Bachmann M. F., Shahinian A., Mak T. W., Ohashi P. S., 1997/04. Transplantation, 63 (7) pp. 1042-4.
[DOI][WoS][Pmid][serval:BIB_BEE1F8B1A9A9]
 
T-cell-independent antiviral B cell responses in CD45-deficient mice
Bachmann M. F., Kundig T. M., Speiser D. E., McKall-Faienza K., Kishara K., Mak T. W., Ohashi P. S., 1997/01. Cellular Immunology, 175 (1) pp. 12-5.
[DOI][WoS][Pmid][serval:BIB_674B825DE490]
1996
 
Tumor necrosis factor receptor p55 mediates deletion of peripheral cytotoxic T lymphocytes in vivo
Speiser D. E., Sebzda E., Ohteki T., Bachmann M. F., Pfeffer K., Mak T. W., Ohashi P. S., 1996/12. European Journal of Immunology, 26 (12) pp. 3055-60.
[DOI][WoS][Pmid][serval:BIB_E02931CBF13F]
 
T cell responses are governed by avidity and co-stimulatory thresholds
Bachmann M. F., Sebzda E., Kundig T. M., Shahinian A., Speiser D. E., Mak T. W., Ohashi P. S., 1996/09. European Journal of Immunology, 26 (9) pp. 2017-22.
[DOI][WoS][Pmid][serval:BIB_A1B26B4CA778]
 
Pretransplant rejection risk assessment through enzyme-linked immunosorbent assay analysis of anti-HLA class I antibodies
Regan J., Monteiro F., Speiser D., Kalil J., Pouletty P., Buelow R., 1996/07. American Journal of Kidney Diseases, 28 (1) pp. 92-8.
[DOI][WoS][Pmid][serval:BIB_6473E7C5BCB5]
 
Pretransplant cytotoxic donor T-cell activity specific to patient HLA class I antigens correlating with mortality after unrelated BMT
Speiser D. E., Loliger C. C., Siren M. K., Jeannet M., 1996/06. British Journal of Haematology, 93 (4) pp. 935-9.
[WoS][Pmid][serval:BIB_F79FD9DFEE9B]
 
High resolution HLA matching associated with decreased mortality after unrelated bone marrow transplantation
Speiser D. E., Tiercy J. M., Rufer N., Grundschober C., Gratwohl A., Chapuis B., Helg C., Loliger C. C., Siren M. K., Roosnek E. et al., 1996/05. Blood, 87 (10) pp. 4455-62.
[WoS][Pmid][serval:BIB_B7F6B55FFAC5]
 
Betrifft: Thiel G: Nierentransplantation und HLA-Matching: izer Richtlinien anderungswurdig? (Schweiz Med Wochenschr 1995; 125:1571-1572). [Concerning: Thiel G: Kidney transplantation and HLA-matching: Do Swiss guidelines deserve to be changed? (Schweiz Med Wochenschr 1995; 125:1571-1572)]
Frick T., Speiser D., 1996/01. Schweizerische Medizinische Wochenschrift, 126 (4) p. 140.
[Pmid][serval:BIB_F76F21369430]
1995
 
Renal transplantation to sensitized patients: decreased graft survival probability associated with a positive historical crossmatch
Speiser D. E., Jeannet M., 1995/12. Transplant Immunology, 3 (4) pp. 330-4.
[Pmid][serval:BIB_EBB422D4BC4B]
 
Histoincompatibilities in ABDR-matched unrelated donor recipient combinations
Rufer N., Tiercy J. M., Breur-Vriesendorp B., Gauchat-Feiss D., Shi X., Slavcev A., Lardy N., Speiser D., Gratwohl A., Chapuis B. et al., 1995/11. Bone Marrow Transplantation, 16 (5) pp. 641-6.
[WoS][Pmid][serval:BIB_DF891C96FFBE]
 
Heterogeneity of HLA-B35. Oligotyping and direct sequencing for B35 subtypes reveals a high mismatching rate in B35 serologically compatible kidney and bone marrow donor/recipient pairs
Gauchat-Feiss D., Rufer N., Speiser D., Jeannet M., Roosnek E., Tiercy J. M., 1995/10. Transplantation, 60 (8) pp. 869-73.
[WoS][Pmid][serval:BIB_BF8DCACC3E7C]
 
Viral peptide specific cytotoxic T lymphocytes are of high avidity to host-MHC but only low avidity to donor-MHC after allogeneic bone marrow transplantation
Kyburz D., Speiser D. E., 1995/06. Transplant Immunology, 3 (2) pp. 143-50.
[Pmid][serval:BIB_26391837BDDA]
 
Immunologische Aspekte der Nierentransplantation in der Schweiz 1981-1992.Swisstransplant Arbeitsgruppe Nierentransplantation [Immunological aspects of kidney transplantation in Switzerland 1981-1992. Swiss Transplant Work Group Kidney Transplantation].
Speiser D.E., Frick T.W., Goumaz C., Opelz G., Jeannet M., 1995. Schweizerische Medizinische Wochenschrift, 125 (34) pp. 1573-1582.
[WoS][Pmid][serval:BIB_133F45481A9D]
1994
 
HLA-DRB1 matched kidneys are preferentially HLA-A and -B compatible and survive longer
Speiser D. E., Jeannet M., Goumaz C., Tiercy J. M., 1994/12. Transplant Immunology, 2 (4) pp. 350-2.
[Pmid][serval:BIB_0D3FD5BE11ED]
 
Oligotyping of HLA-A2, -A3, and -B44 subtypes. Detection of subtype incompatibilities between patients and their serologically matched unrelated bone marrow donors
Tiercy J. M., Djavad N., Rufer N., Speiser D. E., Jeannet M., Roosnek E., 1994/11. Human Immunology, 41 (3) pp. 207-15.
[DOI][WoS][Pmid][serval:BIB_8D747B76EC2C]
 
HLA-B35-subtype mismatches in ABDR serologically matched unrelated donor-recipient pairs
Rufer N., Breur-Vriesendorp B., Tiercy J. M., Gauchat-Feiss D., Shi X., Slavcev A., Lardy N., Chapuis B., Gratwohl A., Speiser D. et al., 1994/09. Human Immunology, 41 (1) pp. 96-101.
[DOI][WoS][Pmid][serval:BIB_59DE1F75D43C]
 
HIV-1 in newborns.
Speiser D.E., Wyler C.A., Siegrist C.A., 1994/06. New England Journal of Medicine, 330 (26) pp. 1905-1906.
[DOI][WoS][Pmid][serval:BIB_4DB4D1ADC12B]
 
Relation between the resolution of HLA-typing and the chance of finding an unrelated bone marrow donor
Speiser D. E., Tiercy J. M., Rufer N., Chapuis B., Morell A., Kern M., Gmur J., Gratwohl A., Roosnek E., Jeannet M., 1994/06. Bone Marrow Transplantation, 13 (6) pp. 805-9.
[WoS][Pmid][serval:BIB_86033B29408E]
1993
 
Specific tolerance to HIV-1 antigens in an infant with rapid progression to AIDS
Siegrist C. A., Wyler C. A., Gerritsen E. J., Perrin L., Speiser D., Suter S., 1993/12. AIDS, 7 (12) pp. 1683-4.
[DOI][WoS][Pmid][serval:BIB_2170DEBF670C]
 
High-resolution histocompatibility testing of a group of sixteen B44-positive, ABDR serologically matched unrelated donor-recipient pairs. Analysis of serologically undisclosed incompatibilities by cellular techniques, isoelectrofocusing, and HLA oligotyping
Rufer N., Breur-Vriesendorp B. S., Tiercy J. M., Slavcev A. S., Lardy N. M., Francis P., Kressig R., Speiser D. E., Helg C., Chapuis B. et al., 1993/11. Human Immunology, 38 (3) pp. 235-9.
[DOI][WoS][Pmid][serval:BIB_19E8FC86981E]
 
Pratransplantare Aktivitat zytotoxischer T-Lymphozyten in nichtverwandten Knochenmarkspender-/-empfanger-Kombinationen mit perfektem HLA-Match. [Pretransplant activity of cytotoxic T-lymphocytes in non-related bone marrow donor/recipient combinations with a perfect HLA match]
Rufer N., Breur B., Tiercy J. M., Speiser D., Chapuis B., Gratwohl A., Jeannet M., Roosnek E., 1993/11. Schweizerische Medizinische Wochenschrift, 123 (47) pp. 2257-8.
[WoS][Pmid][serval:BIB_7C037B17F2FA]
 
Une nouvelle methode de typage HLA-DR par biologie moleculaire: experience d'une annee en transplantation de moelle osseuse. [A new method of HLA-DR typing using molecular biology: 1-year experience in bone marrow transplantation]
Tiercy J. M., Roosnek E., Speiser D., Cros P., Allibert P., Mach B., Jeannet M., 1993/11. Schweizerische Medizinische Wochenschrift, 123 (47) pp. 2259-60.
[WoS][Pmid][serval:BIB_FBABD4B1A9E9]
 
Replacement of HLA class II serology by the HLA-DR microtitre plate oligotyping assay: a one-year experience in unrelated bone marrow donor selection
Tiercy J. M., Roosnek E., Speiser D., Cros P., Allibert P., Mach B., Jeannet M., 1993/10. British Journal of Haematology, 85 (2) pp. 417-8.
[DOI][WoS][Pmid][serval:BIB_4128B0A49AB2]
 
The frequency of pretransplant donor cytotoxic T cell precursors with anti-host specificity predicts survival of patients transplanted with bone marrow from donors other than HLA-identical siblings
Roosnek E., Hogendijk S., Zawadynski S., Speiser D., Tiercy J. M., Helg C., Chapuis B., Gratwohl A., Gmur J., Seger R. et al., 1993/09. Transplantation, 56 (3) pp. 691-6.
[DOI][WoS][Pmid][serval:BIB_B3FDA232EB6D]
 
T cell immunity after a viral infection versus T cell tolerance induced by soluble viral peptides
Kyburz D., Aichele P., Speiser D. E., Hengartner H., Zinkernagel R. M., Pircher H., 1993/08. European Journal of Immunology, 23 (8) pp. 1956-62.
[DOI][WoS][Pmid][serval:BIB_1BD2BD3C5F3A]
 
Lysis of infected cells in vivo by antiviral cytolytic T cells demonstrated by release of cell internal viral proteins
Kyburz D., Speiser D. E., Battegay M., Hengartner H., Zinkernagel R. M., 1993/07. European Journal of Immunology, 23 (7) pp. 1540-5.
[DOI][WoS][Pmid][serval:BIB_E1260FACA4D1]
 
HLA and bone marrow transplantation: techniques and strategy for tissue typing.
Jeannet M., Tiercy J.M., Roosnek E., Speiser D., 1993/06. Nouvelle Revue Française d'Hématologie, 35 (3) pp. 273-274.
[WoS][Pmid][serval:BIB_9AEB664F6F3C]
 
Virus-specific cytotoxic T cell-mediated lysis of lymphocytes in vitro and in vivo
Kyburz D., Speiser D. E., Aebischer T., Hengartner H., Zinkernagel R. M., 1993/06. Journal of Immunology, 150 (11) pp. 5051-8.
[WoS][Pmid][serval:BIB_6CF7F6B569E8]
 
De novo initiation codon mutation (ATG-->ACG) of the beta-globin gene causing beta-thalassemia in a Swiss family
Beris P., Darbellay R., Speiser D., Kirchner V., Miescher P. A., 1993/03. American Journal of Hematology, 42 (3) pp. 248-53.
[DOI][WoS][Pmid][serval:BIB_636E555A10A9]
 
Microangiopathy of cutaneous blood and lymphatic capillaries in chronic venous insufficiency (CVI)
Franzeck U. K., Haselbach P., Speiser D., Bollinger A., 1993/02. Yale Journal of Biology and Medicine, 66 (1) pp. 37-46.
[WoS][Pmid][serval:BIB_CFF0918E8939]
 
Characterization of mixed chimerism in patients with chronic myeloid leukemia transplanted with T-cell-depleted bone marrow: involvement of different hematologic lineages before and after relapse
Roux E., Abdi K., Speiser D., Helg C., Chapuis B., Jeannet M., Roosnek E., 1993/01. Blood, 81 (1) pp. 243-8.
[WoS][Pmid][serval:BIB_45D6A1789B1C]
 
Characterization of pretransplant CTL activity in "perfectly matched" unrelated bone marrow donor/recipient combinations.
Rufer N., Tiercy J.M., Speiser D., Helg C., Gratwohl A., Chapuis B., Jeannet M., Roosnek E., 1993. Bone Marrow Transplantation, 11 (Suppl. 1) pp. 20-23.
[WoS][Pmid][serval:BIB_D268B9139C39]
 
Drug-induced acute pancreatitis: further criticism
Frick T. W., Speiser D. E., Bimmler D., Largiader F., 1993. Digestive Diseases, 11 (2) pp. 113-32.
[DOI][WoS][Pmid][serval:BIB_771B1F0FCE90]
1992
 
Discrepancy between in vitro measurable and in vivo virus neutralizing cytotoxic T cell reactivities. Low T cell receptor specificity and avidity sufficient for in vitro proliferation or cytotoxicity to peptide-coated target cells but not for in vivo protection
Speiser D. E., Kyburz D., Stubi U., Hengartner H., Zinkernagel R. M., 1992/08. Journal of Immunology, 149 (3) pp. 972-80.
[WoS][Pmid][serval:BIB_E0AE574F0704]
 
Kinetics of clonal deletion varies with tolerizing antigen
Schneider R., Pircher H., Speiser D. E., Zinkernagel R., Hengartner H., 1992/08. Thymus, 20 (1) pp. 5-15.
[WoS][Pmid][serval:BIB_4D5A9960F205]
 
Clonal deletion induced by either radioresistant thymic host cells or lymphohemopoietic donor cells at different stages of class I-restricted T cell ontogeny
Speiser D. E., Pircher H., Ohashi P. S., Kyburz D., Hengartner H., Zinkernagel R. M., 1992/05. Journal of Experimental Medicine, 175 (5) pp. 1277-83.
[DOI][WoS][Pmid][serval:BIB_BCC99594F430]
 
T-cell immunoincompetence in allogeneic chimerism
Speiser D. E., Roosnek E., Jeannet M., Zinkernagel R. M., 1992/04. New England Journal of Medicine, 326 (15) pp. 1028-9.
[WoS][Pmid][serval:BIB_C0E004A8C962]
 
Preferential positive selection of V alpha 2+ CD8+ T cells in mouse strains expressing both H-2k and T cell receptor V alpha a haplotypes: determination with a V alpha 2-specific monoclonal antibody
Pircher H., Rebai N., Groettrup M., Gregoire C., Speiser D. E., Happ M. P., Palmer E., Zinkernagel R. M., Hengartner H., Malissen B., 1992/02. European Journal of Immunology, 22 (2) pp. 399-404.
[DOI][WoS][Pmid][serval:BIB_0F9C4B470B97]
 
Extrathymic positive selection of alpha beta T-cell precursors in nude mice
Speiser D. E., Stubi U., Zinkernagel R. M., 1992/01. Nature, 355 (6356) pp. 170-2.
[DOI][WoS][Pmid][serval:BIB_782438A669F1]
1991
 
Microangiopathy in mild chronic venous incompetence (CVI): morphological alterations and increased transcapillary diffusion detected by fluorescence videomicroscopy
Speiser D. E., Bollinger A., 1991/02. International Journal of Microcirculation; Clinical and Experimental, 10 (1) pp. 55-66.
[WoS][Pmid][serval:BIB_27792FDA1BF2]
 
Neonatal tolerance to MIs-1a determinants: deletion or anergy of V beta 6+ T lymphocytes depending upon MHC compatibility of neonatally injected cells
Speiser D. E., Brandle R., Lees R. K., Schneider R., Zinkernagel R. M., MacDonald H. R., 1991/02. International Immunology, 3 (2) pp. 127-34.
[DOI][WoS][Pmid][serval:BIB_CFB0E84B176E]
1990
 
Thymic MHC class I gene regulation of susceptibility to lymphocytic choriomeningitis
Speiser D. E., Zinkernagel R. M., 1990/12. Thymus, 16 (3-4) pp. 187-93.
[WoS][Pmid][serval:BIB_C7948AA53AD9]
 
Distinct fates of self-specific T cells developing in irradiation bone marrow chimeras: clonal deletion, clonal anergy, or in vitro responsiveness to self-Mls-1a controlled by hemopoietic cells in the thymus
Speiser D. E., Chvatchko Y., Zinkernagel R. M., MacDonald H. R., 1990/11. Journal of Experimental Medicine, 172 (5) pp. 1305-14.
[DOI][WoS][Pmid][serval:BIB_EC7C8559E073]
 
Nuclear myxovirus-resistance protein Mx is a minor histocompatibility antigen
Speiser D. E., Zurcher T., Ramseier H., Hengartner H., Staeheli P., Haller O., Zinkernagel R. M., 1990/03. Proceedings of the National Academy of Sciences of the United States of America, 87 (5) pp. 2021-5.
[DOI][WoS][Pmid][serval:BIB_3A5E30D4D470]
1989
 
Positive and negative selection of T cell receptor V beta domains controlled by distinct cell populations in the thymus
Speiser D. E., Lees R. K., Hengartner H., Zinkernagel R. M., MacDonald H. R., 1989/12. Journal of Experimental Medicine, 170 (6) pp. 2165-70.
[DOI][WoS][Pmid][serval:BIB_B5D84C87DE39]
 
Clonal deletion of self-reactive T cells in irradiation bone marrow chimeras and neonatally tolerant mice. Evidence for intercellular transfer of Mlsa
Speiser D. E., Schneider R., Hengartner H., MacDonald H. R., Zinkernagel R. M., 1989/08. Journal of Experimental Medicine, 170 (2) pp. 595-600.
[DOI][WoS][Pmid][serval:BIB_14E6C009C52F]
 
Fate of potentially self-reactive T cells in neonatal mice: analysis of V beta 6+ T cells in Mlsa mice
Schneider R., Lees R., Pedrazzini T., Odermatt B., Speiser D. E., Zinkernagel R. M., Hengartner H., MacDonald H. R., 1989. Thymus, 13 (1-2) pp. 35-43.
[WoS][Pmid][serval:BIB_FC645CE7A5AF]
 
Positive and negative selection of the T-cell antigen receptor repertoire in nontransgenic mice
MacDonald H. R., Speiser D., Lees R., Schneider R., Zinkernagel R. M., Hengartner H., 1989. Cold Spring Harbor Symposia on Quantitative Biology, 54 Pt 1 pp. 129-33.
[Pmid][serval:BIB_783EACF34195]
 
Tolerance to Mlsa by clonal deletion of V beta 6+ T cells in bone marrow and thymus chimeras
Speiser D. E., Kolb E., Schneider R., Pircher H., Hengartner H., MacDonald H. R., Zinkernagel R. M., 1989. Thymus, 13 (1-2) pp. 27-33.
[WoS][Pmid][serval:BIB_FEF0A7CCA332]
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Canton de Vaud
Swiss University